Skip to main content
SpringerLink
Log in

Mood Disorders and Severe Obesity: A Case Study

  • Chapter
  • First Online:
Psychiatric Care in Severe Obesity

  • 1337 Accesses

Abstract

Individuals with mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), have high metabolic disease comorbidity. In particular, the prevalence of obesity is increased among these individuals when compared to the general population. Conversely, obese individuals also have a higher risk of incident depressive and manic symptoms/episodes. Although traditionally mood disorders and obesity have been considered as two separate entities, epidemiological, longitudinal, and clinical studies have shown that the co-occurrence of both conditions do bi-directionally influence each other and alter illness trajectory, presentation, and outcome, leading to the proposal of the “metabolic-mood syndrome.” Consequently, comorbid obesity in persons with a mood disorder is not only a proxy of elevated risk of mortality and increased public health costs, but also a primary therapeutic target. This chapter intends to provide an overview of both mood disorders and obesity, followed by studies examining the presence of obesity in mood disorders and mood disorders in obesity. The subsequent section will examine the emerging paradigm of the “metabolic-mood syndrome” and the various factors that characterize this relationship between mood and metabolism, including genetic, and environment risk factors. An examination of antidepressants and their impact on obesity will also be provided, specifically examining the serotonin norepinephrine re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96.

    Article  PubMed  Google Scholar 

  2. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28.

    Article  PubMed  Google Scholar 

  3. OECD. Health at a glance 2013: OECD indicators. Paris: OECD Publishing; 2013. doi:10.1787/health_glance-2013-en

  4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Toups MS, Myers AK, Wisniewski SR, et al. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom Med. 2013;75(9):863–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126(3):366–87.

    Article  PubMed  Google Scholar 

  7. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–9.

    Article  PubMed  Google Scholar 

  8. Mather AA, Cox BJ, Enns MW, Sareen J. Associations of obesity with psychiatric disorders and suicidal behaviors in a nationally representative sample. J Psychosom Res. 2009;66(4):277–85.

    Article  PubMed  Google Scholar 

  9. Vannucchi G, Toni C, Maremmani I, Perugi G. Does obesity predict bipolarity in major depressive patients? J Affect Disord. 2014;155:118–22.

    Article  PubMed  Google Scholar 

  10. Kemp DE, Sylvia LG, Calabrese JR, et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand. 2014;129(1):24–34.

    Article  CAS  PubMed  Google Scholar 

  11. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–31.

    Article  Google Scholar 

  12. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2014;52:89–104.

    Article  Google Scholar 

  13. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry. 2007;19(4):257–64.

    Article  PubMed  Google Scholar 

  14. American Psychiatric Association. DSM 5—Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: APA; 2013

    Google Scholar 

  15. Harald B, Gordon P. Meta-review of depressive subtyping models. J Affect Disord. 2012;139(2):126–40.

    Article  PubMed  Google Scholar 

  16. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013;18(5):595–606.

    Article  CAS  PubMed  Google Scholar 

  17. Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, et al. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 2013;13(7):827–42.

    Article  CAS  PubMed  Google Scholar 

  18. Strakowski SM, Adler CM, Almeida J, et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012;14(4):313–25.

    Article  PubMed  Google Scholar 

  19. Bowden CL, Perlis RH, Thase ME, et al. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012;18(3):243–9.

    Article  CAS  PubMed  Google Scholar 

  20. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41–50.

    Article  CAS  PubMed  Google Scholar 

  21. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217–24.

    Article  PubMed  Google Scholar 

  22. Despres JP. Health consequences of visceral obesity. Ann Med. 2001;33(8):534–41.

    Article  CAS  PubMed  Google Scholar 

  23. Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310(20):2147–8.

    Article  CAS  PubMed  Google Scholar 

  24. Naukkarinen J, Rissanen A, Kaprio J, Pietilainen KH. Causes and consequences of obesity: the contribution of recent twin studies. Int J Obes (Lond). 2012;36(8):1017–24.

    Article  CAS  Google Scholar 

  25. Hussain SS, Bloom SR. The regulation of food intake by the gut–brain axis: implications for obesity. Int J Obes (Lond). 2013;37(5):625–33.

    Article  CAS  Google Scholar 

  26. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6.

    Article  CAS  PubMed  Google Scholar 

  27. Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. J Am Coll Cardiol. 2014;63(11):1071–8.

    Article  PubMed  Google Scholar 

  28. Marques-Vidal P, Pecoud A, Hayoz D, et al. Prevalence of normal weight obesity in Switzerland: effect of various definitions. Eur J Nutr. 2008;47(5):251–7.

    Article  PubMed  Google Scholar 

  29. Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56(4):426–33.

    Article  PubMed  Google Scholar 

  30. Jialin W, Yi Z, Weijie Y. Relationship between body mass index and mortality in hemodialysis patients: a meta-analysis. Nephron Clin Pract. 2012;121(3–4):c102–11.

    Article  PubMed  Google Scholar 

  31. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13–22.

    Article  PubMed  Google Scholar 

  32. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry. 1996;53:391–9.

    Article  CAS  PubMed  Google Scholar 

  34. Pine DS, Cohen P, Brook J, et al. Psychiatry symptoms in adolescence as predictors of obesity in early adulthood: a longitudinal study. Am J Public Health. 1997;97:1303–10.

    Article  Google Scholar 

  35. Roberts RE, Deleger S, Strawbridge WJ, et al. Prospective association between obesity and depression: evidence from Alameda County Study. Int J Obes Relat Metab Disord. 2003;27:514–21.

    Article  CAS  PubMed  Google Scholar 

  36. Hasler G, Merikangas K, Eich D, et al. Psychopathology as a risk factor for being overweight. In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatry Association, San Francisco, CA, 17–22 May 2003. NR106:39–40.

    Google Scholar 

  37. Muller-Oelinghausen B, Passoth P-M, Poser W, et al. Imapaired glucose tolerance in long-term lithium-treated patients. Int Pharmacopsychiatry. 1979;14:350–62.

    Google Scholar 

  38. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207–13.

    Article  PubMed  Google Scholar 

  39. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;60:112–7.

    Article  Google Scholar 

  40. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51(5):274–80.

    PubMed  Google Scholar 

  41. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–30.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13:387–95.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Petry NM, Barry D, Pietrzak RH, et al. Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288–97.

    Article  PubMed  Google Scholar 

  44. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634–51.

    Article  PubMed  Google Scholar 

  45. Black DW, Goldstein RB, Mason EE. Prevalence of mental disorders in 88 morbidly obese bariatric clinic patients. Am J Psychiatry. 1992;149:227–34.

    Article  CAS  PubMed  Google Scholar 

  46. Britz B, Siegfried W, Ziegler A, et al. Rates of psychiatry disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. Int J Obes. 2000;24:1707–14.

    Article  CAS  Google Scholar 

  47. Cizza G, Ronsaville DS, Kleitz H, et al. Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. PLoS One. 2012;7(1):e28912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Glaus J, Vandeleur C, Gholam-Rezaee M, et al. Atypical depression and alcohol misuse are related to the cardiovascular risk in the general population. Acta Psychiatr Scand. 2013;128(4):282–93.

    CAS  PubMed  Google Scholar 

  49. Lamers F, de Jonge P, Nolen WA, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71(12):1582–9.

    Article  PubMed  Google Scholar 

  50. Levitan RD, Davis C, Kaplan AS, Arenovich T, Phillips DI, Ravindran AV. Obesity comorbidity in unipolar major depressive disorder: refining the core phenotype. J Clin Psychiatry. 2012;73(8):1119–24.

    Article  PubMed  Google Scholar 

  51. Byers AL, Vittinghoff E, Lui LY, et al. Twenty-year depressive trajectories among older women. Arch Gen Psychiatry. 2012;69(10):1073–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Marijnissen RM, Bus BA, Holewijn S, et al. Depressive symptom clusters are differentially associated with general and visceral obesity. J Am Geriatr Soc. 2011;59(1):67–72.

    Article  PubMed  Google Scholar 

  53. Simon GE, Ludman EJ, Linde JA, et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry. 2008;30(1):32–9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry. 2010;71(4):391–9.

    Article  PubMed  Google Scholar 

  55. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12(4):404–13.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Khan A, Schwartz KA, Kolts RL, Brown WA. BMI, sex, and antidepressant response. J Affect Disord. 2007;99(1–3):101–6.

    Article  CAS  PubMed  Google Scholar 

  57. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321–6.

    Article  PubMed  Google Scholar 

  58. Oskooilar N, Wilcox CS, Tong ML, Grosz DE. Body mass index and response to antidepressants in depressed research subjects. J Clin Psychiatry. 2009;70(11):1609–10.

    Article  PubMed  Google Scholar 

  59. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):59–63.

    Article  PubMed  Google Scholar 

  60. Uher R, Mors O, Hauser J, et al. Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord. 2009;118(1–3):147–54.

    Article  CAS  PubMed  Google Scholar 

  61. Busch AM, Whited MC, Appelhans BM, et al. Reliable change in depression during behavioral weight loss treatment among women with major depression. Obesity (Silver Spring). 2013;21(3):E211–8.

    Article  Google Scholar 

  62. Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry. 2006;163(1):109–14.

    Article  PubMed  Google Scholar 

  63. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552–62.

    Article  CAS  PubMed  Google Scholar 

  64. Afari N, Noonan C, Goldberg J, et al. Depression and obesity: do shared genes explain the relationship? Depress Anxiety. 2010;27(9):799–806.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Jokela M, Elovainio M, Keltikangas-Jarvinen L, et al. Body mass index and depressive symptoms: instrumental-variables regression with genetic risk score. Genes Brain Behav. 2012;11(8):942–8.

    CAS  PubMed  Google Scholar 

  66. Samaan Z, Anand SS, Zhang X, et al. The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. Mol Psychiatry. 2013;18(12):1281–6.

    Article  CAS  PubMed  Google Scholar 

  67. Rivera M, Cohen-Woods S, Kapur K, et al. Depressive disorder moderates the effect of the FTO gene on body mass index. Mol Psychiatry. 2012;17(6):604–11.

    Article  CAS  PubMed  Google Scholar 

  68. Altman S, Haeri S, Cohen LJ, et al. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract. 2006;12(5):269–82.

    Article  PubMed  Google Scholar 

  69. Horesh N, Iancu I. A comparison of life events in patients with unipolar disorder or bipolar disorder and controls. Compr Psychiatry. 2010;51(2):157–64.

    Article  PubMed  Google Scholar 

  70. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006;1083:77–110.

    Article  CAS  PubMed  Google Scholar 

  71. Lai JS, Hiles S, Bisquera A, Hure AJ, McEvoy M, Attia J. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr. 2014;99(1):181–97.

    Article  CAS  PubMed  Google Scholar 

  72. Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J Affect Disord. 2013;148(1):12–27.

    Article  PubMed  Google Scholar 

  73. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 2012;169(2):141–51.

    Article  PubMed  Google Scholar 

  74. Lee C, Tsenkova V, Carr D. Childhood trauma and metabolic syndrome in men and women. Soc Sci Med. 2014;105:122–30.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.

    Article  CAS  PubMed  Google Scholar 

  76. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.

    Article  CAS  PubMed  Google Scholar 

  77. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1–2):16–27.

    Article  CAS  PubMed  Google Scholar 

  78. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013;14(3):232–44.

    Article  CAS  PubMed  Google Scholar 

  79. Milaneschi Y, Sutin AR, Terracciano A, et al. The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology. 2014;42:1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Liao Y, Huang X, Wu Q, et al. Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. J Psychiatry Neurosci. 2013;38(1):49–56.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Lin F, Weng S, Xie B, Wu G, Lei H. Abnormal frontal cortex white matter connections in bipolar disorder: a DTI tractography study. J Affect Disord. 2011;131(1–3):299–306.

    Article  PubMed  Google Scholar 

  82. Vederine FE, Wessa M, Leboyer M, Houenou J. A meta-analysis of whole-brain diffusion tensor imaging studies in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8):1820–6.

    Article  PubMed  Google Scholar 

  83. Garcia-Garcia I, Jurado MA, Garolera M, et al. Functional connectivity in obesity during reward processing. Neuroimage. 2012;66C:232–9.

    Google Scholar 

  84. Kullmann S, Heni M, Veit R, et al. The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum Brain Mapp. 2012;33(5):1052–61.

    Article  PubMed  Google Scholar 

  85. Cole JH, Boyle CP, Simmons A, et al. Body mass index, but not FTO geno-type or major depressive disorder, influences brain structure. Neuroscience. 2013;252:109–17.

    Article  CAS  PubMed  Google Scholar 

  86. Kuswanto CN, Sum MY, Yang GL, Nowinski WL, McIntyre RS, Sim K. Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. Psychol Med. 2014;44(3):533–41.

    Article  CAS  PubMed  Google Scholar 

  87. Cota D, Tschop MH, Horvath TL, Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev. 2006;51(1):85–107.

    Article  CAS  PubMed  Google Scholar 

  88. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;14(9):609–25.

    Article  CAS  PubMed  Google Scholar 

  89. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci. 2011;15(1):37–46.

    Article  CAS  PubMed  Google Scholar 

  90. D’Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405(1–3):365–73.

    Article  PubMed  Google Scholar 

  91. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits. 2014;7(9):489–99.

    PubMed  PubMed Central  Google Scholar 

  92. Anand A, Barkay G, Dzemidzic M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13(4):406–13.

    Article  PubMed  Google Scholar 

  93. Camardese G, Di Giuda D, Di Nicola M, et al. Imaging studies on dopamine transporter and depression: a review of literature and suggestions for future research. J Psychiatr Res. 2014;51:7–18.

    Article  CAS  PubMed  Google Scholar 

  94. Chang TT, Yeh TL, Chiu NT, et al. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. Bipolar Disord. 2010;12(1):102–6.

    Article  PubMed  Google Scholar 

  95. Brady Jr RO, Cooper A, Jensen JE, et al. A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder. Transl Psychiatry. 2012;2:e160.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Chu WJ, Delbello MP, Jarvis KB, et al. Magnetic resonance spectroscopy imaging of lactate in patients with bipolar disorder. Psychiatry Res. 2013;213(3):230–4.

    Article  CAS  PubMed  Google Scholar 

  97. Iosifescu DV, Renshaw PE. 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression? Harv Rev Psychiatry. 2003;11(2):51–63.

    PubMed  Google Scholar 

  98. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder—a systematic review and meta-analysis. Psychiatry Res. 2012;203(2–3):111–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900–19.

    Article  CAS  PubMed  Google Scholar 

  100. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol. 2008;63(5):652–7.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Gazdzinski S, Millin R, Kaiser LG, et al. BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. Obesity (Silver Spring). 2010;18(4):743–8.

    Article  Google Scholar 

  102. Schmoller A, Hass T, Strugovshchikova O, et al. Evidence for a relationship between body mass and energy metabolism in the human brain. J Cereb Blood Flow Metab. 2010;30(7):1403–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Cowansage KK, LeDoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol. 2010;3(1):12–29.

    Article  CAS  PubMed  Google Scholar 

  104. Zagrebelsky M, Korte M. Form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacology. 2014;76(Pt C):628–38.

    Article  CAS  PubMed  Google Scholar 

  105. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11(6):763–73.

    Article  PubMed  Google Scholar 

  106. Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995–1004.

    Article  PubMed  Google Scholar 

  107. Burkhalter J, Fiumelli H, Allaman I, Chatton JY, Martin JL. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci. 2003;23(23):8212–20.

    CAS  PubMed  Google Scholar 

  108. Markham A, Cameron I, Bains R, et al. Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. Eur J Neurosci. 2012;35(3):366–74.

    Article  PubMed  Google Scholar 

  109. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of BDNF in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci. 2007;27(52):14265–74.

    Article  CAS  PubMed  Google Scholar 

  110. Xu B, Goulding EH, Zang K, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6(7):736–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther. 2011;36(1):10–8.

    Article  CAS  PubMed  Google Scholar 

  112. Di Marzo V, Despres JP. CB1 antagonists for obesity—what lessons have we learned from rimonabant? Nat Rev Endocrinol. 2009;5(11):633–8.

    Article  PubMed  CAS  Google Scholar 

  113. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005;102(51):18620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet. 2007;370(9600):1671–2.

    Article  PubMed  Google Scholar 

  115. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008;54(1):141–50.

    Article  CAS  PubMed  Google Scholar 

  116. Bennetzen MF, Wellner N, Ahmed SS, et al. Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss. Int J Obes (Lond). 2011;35(11):1377–84.

    Article  CAS  Google Scholar 

  117. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Di Marzo V, Cote M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2009;52(2):213–7.

    Article  CAS  PubMed  Google Scholar 

  119. Matias I, Gatta-Cherifi B, Tabarin A, et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One. 2012;7(7):e42399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. McElroy SL, Keck PE. Metabolic syndrome in bipolar disorder. J Clin Psychiatry. 2014;75(January):46–61.

    Article  CAS  PubMed  Google Scholar 

  121. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7):1199–201.

    Article  PubMed  Google Scholar 

  122. Malhotra S, King KH, Welge JA, et al. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry. 2002;63:802–6.

    Article  CAS  PubMed  Google Scholar 

  123. Uguz F, Sahingoz M, Gungor B, Akosv F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015;37(1):46–8.

    Article  PubMed  Google Scholar 

  124. Leombruni P, Lavagnino L, Gastaldi F, et al. Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial. Hum Psychopharmacol. 2009;24:483–8.

    Article  CAS  PubMed  Google Scholar 

  125. Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorder: a placebo controlled trial. Int J Eat Disord. 2012;45(2):281–9.

    Article  PubMed  Google Scholar 

  126. Gardiner HM, Freeman CP, Jesinger DK, et al. Fluvoxamine: an open pilot study in moderate obese female patients suffering from atypical eating disorders and episodes of bingeing. Int J Obes Relat Metab Disord. 1993;17(5):301–5.

    CAS  PubMed  Google Scholar 

  127. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998;155:1756–62.

    Article  CAS  PubMed  Google Scholar 

  128. Pearlstein T, Spurell E, Hohlstein LA, et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health. 2003;6:147–51.

    Article  CAS  PubMed  Google Scholar 

  129. McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157:1004–46.

    Article  CAS  PubMed  Google Scholar 

  130. Milano W, Petrella C, Capasso A. Treatment of binge eating disorder with sertraline: a randomized controlled trial. Biomed Res. 2005;16:89–91.

    CAS  Google Scholar 

  131. Leombruni P, Pierò A, Brustolin A, et al. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol. 2006;21:181–8.

    Article  CAS  PubMed  Google Scholar 

  132. Greeno CG, Wing RR. A double blind, placebo-controlled trial of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr. 1996;64:267–73.

    CAS  PubMed  Google Scholar 

  133. Arnold LM, McElroy SL, Hudson JI, et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 2002;63:1028–33.

    Article  CAS  PubMed  Google Scholar 

  134. McElroy SL, Hudson JI, Malhotra S, et al. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry. 2003;64:807–13.

    Article  CAS  PubMed  Google Scholar 

  135. Guerdjikova AL, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008;23:1–11.

    Article  CAS  PubMed  Google Scholar 

  136. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544–51.

    Article  CAS  PubMed  Google Scholar 

  137. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049–56.

    Article  CAS  PubMed  Google Scholar 

  138. Calandra C, Russo RG, Luca M. Bupropion versus Sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study. Psychiatr Q. 2012;83:177–85.

    Article  PubMed  Google Scholar 

  139. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–606.

    Article  CAS  PubMed  Google Scholar 

  140. Halpern B, Oliveira ESL, Faria AM, et al. Combinations of drugs in the treatment of obesity. Pharmaceuticals. 2010;3:2398–415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV, Oefinger M, Crum RM, Charleston J, Casagrande SS, Guallar E, Goldberg RW, Campbell LM, Appel LJ. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Keranen AM, Rasinaho E, Hakko H, Savolainen M, Lindeman S. Eating behavior in obese and overweight persons with and without anhedonia. Appetite. 2010;55(3):726–9.

    Article  PubMed  Google Scholar 

  143. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005;6(3):221–34.

    Article  CAS  PubMed  Google Scholar 

  144. Calkin C, van de Velde C, Ruzickova M, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11(6):650–6.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):730–43.

    Article  CAS  PubMed  Google Scholar 

  146. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond). 2006;110(2):143–52.

    Article  CAS  Google Scholar 

  147. Kendler KS, Aggen SH, Neale MC. Evidence for multiple genetic factors underlying DSM-IV criteria for major depression. JAMA Psychiatry. 2013;70(6):599–607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. McElroy SL. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry. 2009;70 suppl 3:12–21.

    Article  PubMed  Google Scholar 

  149. McIntyre RS, Muzina DJ, Kemp DE, et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep. 2008;10(1):66–72.

    Article  PubMed  Google Scholar 

  150. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J. Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. J Psychopharmacol. 2014;28(9):866–73.

    Article  PubMed  CAS  Google Scholar 

  152. Volkow ND, Wang GJ, Fowler JS, Telang F. Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3191–200.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Department of Molecular Medicine and Development, University of Siena School of Medicine, Viale Bracci, 1, Via XXIV Maggio, 23, Siena, 53100, Italy

    Giovanni Amodeo M.D.

  2. Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada, M5T 2S8

    Mehala Subramaniapillai H.B.Sc., M.Sc., Rodrigo B. Mansur M.D. & Roger S. McIntyre M.D., F.R.C.P.C. (Executive Director)

  3. Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada

    Roger S. McIntyre M.D., F.R.C.P.C. (Executive Director)

  4. Brain and Cognition, Discovery Foundation (BCDF), University of Toronto, Toronto, ON, Canada

    Roger S. McIntyre M.D., F.R.C.P.C. (Executive Director)

Authors
  1. Giovanni Amodeo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehala Subramaniapillai H.B.Sc., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rodrigo B. Mansur M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roger S. McIntyre M.D., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehala Subramaniapillai H.B.Sc., M.Sc. .

Editor information

Editors and Affiliations

  1. Toronto Western Hospital Bariatric Surgery Program, Centre for Mental Health, University Health Network, Toronto, Ontario, Canada

    Sanjeev Sockalingam

  2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    Raed Hawa

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Amodeo, G., Subramaniapillai, M., Mansur, R.B., McIntyre, R.S. (2017). Mood Disorders and Severe Obesity: A Case Study. In: Sockalingam, S., Hawa, R. (eds) Psychiatric Care in Severe Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-42536-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42536-8_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42534-4

  • Online ISBN: 978-3-319-42536-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation